The results of a large clinical trial show that the investigational immunotherapy tebentafusp, a bispecific fusion protein, improves overall survival in patients with metastatic uveal melanoma. There is no standard treatment for the disease and, once it has spread, many patients do not survive for a year.

Researchers have shown that the loss of a protein called AMBRA1 can cause tumors to form in mice and is linked with worse outcomes in some human tumors. A lack of AMBRA1 may make some tumors resistant to CDK4/6 inhibitor drugs. The new research may lead to strategies for re-sensitizing cancer cells to these drugs.

In people with advanced esophageal cancer, combining nivolumab (Opdivo) with either chemotherapy or ipilimumab (Yervoy) improved how long they lived, according to results from a large clinical trial. Results from the trial, CheckMate 648, should change current clinical practice, experts said.

In people with advanced esophageal cancer, combining nivolumab (Opdivo) with either chemotherapy or ipilimumab (Yervoy) improved how long they lived, according to results from a large clinical trial. Results from the trial, CheckMate 648, should change current clinical practice, experts said.

A drug called avasopasem manganese (AVA), which has been found to protect normal tissues from radiation therapy, can also make cancer cells more vulnerable to radiation treatment, a new study in mice suggests. AVA is already being tested in early clinical trials against several cancers, including pancreatic cancer.

People with advanced melanoma treated with two immunotherapy drugs—nivolumab (Opdivo) and a new drug called relatlimab, which targets a protein called LAG-3—lived longer without their cancer getting worse than those treated only with nivolumab, according to results from a large clinical trial.